证券代码：002082 证券简称：万邦德 公告编号：2025-044 万邦德医药控股集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 注册资本：陆亿壹仟壹佰陆拾捌万玖仟零伍拾伍元 万邦德医药控股集团股份有限公司(以下简称"公司"）于 2025 年 3 月 11 日 和 2025 年 3 月 27 日分别召开了第九届董事会第十三次会议和 2025 年第二次临时 股东大会，会议审议通过了《关于注销回购股份暨减少注册资本的议案》，于 2025 年 4 月 27 日和 2025 年 5 月 20 日分别召开了第九届董事会第十四次会议和 2024 年年度股东大会，会议审议通过了《关于变更公司经营范围及修订<公司章程>的 议案》。公司注册资本由人民币 616,689,055 元变更为 611,689,055 元。具体内 容详见公司于 2025 年 4 月 29 日和 2025 年 5 月 6 日在巨潮资讯网 （www.cninofo.com.cn）等指定披露媒体披露的《关于变更公司经营范围及修订< 公司章程>的公告》（公告编号：2025-027）和《关于回购股份注销完成暨股份变 动的公告》（公告编号：2025- ...

证券代码：002082 证券简称：万邦德 公告编号：2025-045 万邦德医药控股集团股份有限公司 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 | （二）业绩预告情况：预计净利润同向下降 | | --- | | 项 | 目 | 本报告期 | | | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 归属于上市 公司股东的 | | 盈利：1,080 | 万元 | — | 1,550 | 万元 | 盈利：3,770.41 | 万元 | | 净利润 | | 比上年同期下降：58.89% — | | | | 71.36% | | | | 扣除非经常 性损益后的 | | 盈利：-2,510 | 万元 | — | -1,400 | 万元 | 盈利：1,807.29 | 万元 | | 净利润 | | 比上年同期下降：177.46% — | | | | 238.88% | | | | 基本每股收 益 | | 盈利：0.018 | 元/股 | — | 0.025 | 元/股 | 盈利：0.06 ...

Core Viewpoint - Wanbond's subsidiary has obtained a patent for a novel composition aimed at treating Alzheimer's disease and skin photoaging, highlighting innovation in drug development [1] Group 1: Patent Acquisition - Wanbond's wholly-owned subsidiary, Wanbond Pharmaceutical Group Co., Ltd., has received an invention patent certificate from the National Intellectual Property Administration [1] - The patent is for a composition and formulation that combines ginseng, ginkgo biloba leaves, and a specific herb, representing a first-class new drug compound [1] Group 2: Product Characteristics - The patented composition is characterized by high safety, low dosage, simple drug composition, and improved efficacy compared to existing single-agent medications [1] - The innovative therapy integrates multiple components, targets, and pathways to intervene in the pathological network of Alzheimer's disease, offering a superior treatment option for patients [1]

Core Viewpoint - The report outlines a share transfer agreement involving Wanbangde Pharmaceutical Holdings Group Co., Ltd., where a total of 60,000,000 shares, representing 9.8089% of the company's total equity, will be transferred to Wenzhou Wanlong Pharmaceutical Technology Partnership (Limited Partnership) through a private agreement [1][9]. Group 1: Shareholding Changes - Prior to the transfer, the information disclosing parties collectively held 308,747,078 shares, accounting for 50.4745% of the total equity of the company [7]. - After the transfer, the shareholding of the information disclosing parties will decrease to 248,747,078 shares, representing 40.6656% of the total equity [7]. - The specific shareholding changes include Wanbangde Group reducing its shares from 193,426,693 (31.6217%) to 176,387,367 (28.8361%), Zhao Shouming from 49,677,267 (8.1213%) to 37,267,267 (6.0925%), and others accordingly [7]. Group 2: Share Transfer Agreement Details - The share transfer agreement specifies that the shares will be sold at a price of 6.88 RMB per share, totaling 412,800,000 RMB for the entire transaction [9][10]. - The agreement outlines that the transfer will be executed within five trading days after obtaining the necessary confirmations from the Shenzhen Stock Exchange [10]. - The parties involved in the transfer include Wanbangde Group, Zhao Shouming, and others, with the receiving party being Wenzhou Wanlong Pharmaceutical [9][10]. Group 3: Compliance and Future Plans - The share transfer is subject to compliance confirmation and registration procedures with the Shenzhen Securities Registration and Settlement Company [2][11]. - As of the report date, the information disclosing parties have no plans to increase or further reduce their shareholding in the company within the next 12 months [5][14]. - The report confirms that there are no outstanding debts or guarantees that could harm the interests of the company or its shareholders related to the share transfer [15].

Core Viewpoint - The report outlines a significant equity change involving Wanbangde Pharmaceutical Holdings Group Co., Ltd., where the information disclosure obligor, Wenling Wanlong Pharmaceutical Technology Partnership (Limited Partnership), is set to acquire 60 million shares, representing 9.8089% of the company's total equity through a private transfer agreement [1][4]. Group 1: Equity Change Details - The equity change is a result of an agreement signed on July 11, 2025, between Wenlong Pharmaceutical and several transferors, including Zhao Shouming and Zhuang Hui, to transfer a total of 60 million shares [1][5]. - The transfer price is set at 6.88 RMB per share, totaling 412.8 million RMB for the entire transaction [5][6]. - The transferors include Zhao Shouming (12,410,000 shares), Zhuang Hui (7,050,000 shares), and others, with the largest transferor being Wanbangde Group (17,039,326 shares) [5][6]. Group 2: Compliance and Future Plans - The equity change must comply with the regulations of the Shenzhen Stock Exchange and requires the completion of share transfer registration with the China Securities Depository and Clearing Corporation [2][6]. - The information disclosure obligor commits not to reduce its holdings of the acquired shares within 12 months following the completion of the transfer [3][4]. - There are no plans for the information disclosure obligor to increase its stake in the company within the next 12 months [3][4].

Summary of Key Points Core Viewpoint - The announcement details the agreement for the transfer of 60,000,000 shares of Wanbangde Pharmaceutical Holdings Group Co., Ltd., representing 9.8089% of the total share capital, from its controlling shareholders to Wanzhong Medicine, with a transfer price of 6.88 RMB per share, totaling approximately 412.8 million RMB [1][2][5]. Group 1: Agreement Overview - The transfer involves Wanbangde Group, its actual controllers Zhao Shouming and Zhuang Hui, and their concerted actions, transferring shares to Wanzhong Medicine [1][2]. - The total transfer price is set at 6.88 RMB per share, amounting to 412.8 million RMB for the entire transaction [2][5]. - The transaction is subject to compliance review by the Shenzhen Stock Exchange before the transfer can be completed [3][6]. Group 2: Shareholding Changes - Following the transfer, the shareholding structure will change, with Wanbangde Group's stake decreasing from 31.6217% to 28.8361%, and Zhao Shouming's from 8.1213% to 6.0925% [2][3]. - Wanzhong Medicine will acquire 60,000,000 shares, establishing a new ownership stake of 9.8089% in the company [2][5]. Group 3: Impact on Company Control - The transfer does not trigger a change in control, as the combined shareholding of the controlling shareholders will remain at 40.6656% post-transaction [7][8]. - The governance structure and ongoing operations of the company are not expected to be significantly affected by this share transfer [7][8]. Group 4: Compliance and Restrictions - Wanzhong Medicine has committed not to sell the acquired shares for twelve months following the completion of the transfer [2][7]. - The transaction adheres to relevant regulations, including the Management Measures for the Acquisition of Listed Companies and the Shenzhen Stock Exchange's guidelines [3][8].

证券代码：002082 证券简称：万邦德 公告编号：2025-042 万邦德医药控股集团股份有限公司 关于控股股东、实际控制人及一致行动人 拟协议转让公司部分股份暨权益变动的提示性公告 公司控股股东、实际控制人及其一致行动人和受让方保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、万邦德医药控股集团股份有限公司（以下简称"公司"）控股股东万邦 德集团有限公司（以下简称"万邦德集团"）、实际控制人赵守明先生、庄惠女 士、一致行动人温岭惠邦投资咨询有限公司（以下简称"温岭惠邦"）、温岭富 邦投资咨询有限公司（以下简称"温岭富邦"）拟通过协议转让方式，向温岭市 万龙医药科技合伙企业（有限合伙）(以下简称"万龙医药"）转让其持有的公 司股票合计 60,000,000 股，占公司总股本的 9.8089%。（以下简称"本次交易"） 2、本次交易不涉及要约收购，不涉及关联交易。 3、本次交易不会导致公司控制权发生变化，不会对公司治理结构及持续经 营产生重大影响。 4、本次交 ...

万邦德医药控股集团股份有限公司 简式权益变动报告书 上市公司名称：万邦德医药控股集团股份有限公司 上市地点：深圳证券交易所 股票简称：万邦德 股票代码：002082.SZ 信息披露义务人：温岭市万龙医药科技合伙企业（有限合伙） 主要经营场所：浙江省台州市温岭市城东街道阳光大道157号科创大厦13楼 1309室 股份变动性质：股份增加（协议转让） 签署日期：2025年7月11日 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在万邦德医药控股集团股份有限公司拥有 权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述 信息披露义务人没有通过任何其他方式增加或减少其在万邦德中拥有权益的股 份。 四、 ...

万邦德医药控股集团股份有限公司 简式权益变动报告书 上市公司名称：万邦德医药控股集团股份有限公司 信息披露义务人一：万邦德集团有限公司 住所及通讯地址：浙江省台州市温岭市城东街道楼山村百丈路西侧 信息披露义务人二：赵守明 住所及通讯地址：浙江省温岭市**** 信息披露义务人三：庄惠 住所及通讯地址：浙江省温岭市**** 信息披露义务人四：温岭惠邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 信息披露义务人五：温岭富邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 股份变动性质：股份减少（协议转让） 签署日期：二〇二五年七月十一日 上市地点：深圳证券交易所 股票简称：万邦德 股票代码：002082.SZ 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和 ...

万邦德：控股股东等拟协议转让公司9.8089%股份 智通财经7月11日电，万邦德(002082.SZ)公告称，公司控股股东万邦德集团、实际控制人赵守明、庄 惠、一致行动人温岭惠邦、温岭富邦拟通过协议转让方式，向温岭市万龙医药科技合伙企业转让其持有 的公司股票合计6000万股，占公司总股本的9.8089%。转让价格为6.88元/股，股份转让总价款合计为 4.128亿元。 ...